Thin-layer cytology meets viral hybrid capture. This commentary addresses the benefits of liquid-based thin-layer cervical cytology, and the applicability of residual samples for human papilloma virus assay. The potential for use of this technology in wide-scale screening as well as the many unanswered issues, in particular cost-benefit ratio and financing, are also discussed.